The Patent Trial and Appeal Board said that challenged claims of The Johns Hopkins University’s patent directed to anti-cancer therapies that block immune system checkpoints in several different types of cancer patients are unpatentable as anticipated by and obvious over prior art, in an inter partes review by Merck Sharp & Dohme LLC. The board determined that the challenged claims are anticipated by and obvious over various combinations of prior art, including prior art that reports a phase 2 study of MK-3475 in patients with microsatellite unstable tumors, titled “Colorectal Cancer and Immunity: What We Know and Perspectives,” and titled ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.